Aspen Aerogels lifts third-quarter sales 17% but guides lower after plant incident

Aspen Aerogels grew third-quarter 2026 revenue to $85.2m, up from $73.0m a year earlier, an increase of roughly 17%. The company reported on 5 November. Even so, it recorded a net loss of $10.4m, with adjusted EBITDA of $19.8m.

The gap between the top line and the bottom line owes much to $15.1m of costs tied to an incident at the company's East Providence facility. Aspen said it is pursuing insurance claims. The summary available to CompePharma does not say what caused the incident, how much of the site was affected, or how far the claims have progressed, so how much of the cost might be recovered is unknown.

Aspen expects restoration work at East Providence to finish in the first half of 2027. For the fourth quarter of 2026 it guided to revenue of $60m to $75m. That is about 12% to 30% below the third-quarter figure, though the company's materials do not link the lower range to the facility.

On the commercial side, the company pointed to its first order for data centre infrastructure and early revenue from battery energy storage. No order size or revenue figures were given for either.

Aspen is not a pharma or biotech company, and the information provided states no regulatory or pharmacovigilance implications. The update is mainly relevant to teams that buy its products or depend on its facilities.